AbD Serotec plans to launch series of novel anti-drug antibodies pharmabiz.com Starting with the recent launch of fully human, recombinant antibodies binding Rituximab (Rituxan) and Trastuzumab (Herceptin), AbD Serotec plans to expand this product category with antibodies against Alemtuzumab (Campath), Bevacizumab (Avastin), ... |
